Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
- Status
- COMPLETED
- Phase
- PHASE1
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)
- Status
- COMPLETED
- Phase
- PHASE3
Surgical Pembro +/- Olaparib w TMZ for rGBM
- Status
- RECRUITING
- Phase
- PHASE2
MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Doravirine and Weight Gain in Antiretroviral Naive
- Status
- WITHDRAWN
- Phase
- PHASE3
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
- Status
- COMPLETED
- Phase
- PHASE2